title: Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES.
abstract: BACKGROUND
  Changes in lipid levels over time after acquiring HCV infection, and how they differ from HCV-uninfected persons are unknown.
  
  
  METHODS
  We used ERCHIVES to identify those with a known HCV seroconversion window and persistently negative controls. We excluded subjects with HIV and hepatitis B and those who received lipid lowering agents. Total Cholesterol (TC), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG) and non-HDL cholesterol were retrieved at yearly intervals and plotted over time.
  
  
  RESULTS
  Among 1,270 HCV+ and 5,070 HCV- subjects, median age [IQR] was 47[37,53] for HCV+ and 52[47,57] for the HCV- group; 69% were White and 91% were males in each group. Mean BMI [SD] was 26.94[6.73] in the HCV+ and 28.15 [5.98] in the HCV- group (P < 0.001). Over a 10-year follow-up period among HCV+ persons, TC decreased by (mean (SD) mg/dL) 12.06(36.95), LDL by 9.22(31.44), TG by 13.58(87.01) and non-HDL-C by 12.55(35.14). Among HCV- persons, TC cholesterol decreased by 4.15(31.21), LDL by 4.16(26.51); TG by 4.42(82.34) and non-HDL-C by 5.78(30.17).
  
  
  CONCLUSIONS
  After HCV acquisition, TC, LDL, TG and non-HDL-C progressively decline over time independent of BMI and liver fibrosis. Consequences of lipid changes and the need and optimal timing of lipid lowering therapy in HCV+ persons require further study.
authors.affiliation: VA Pittsburgh Healthcare System, 3601 Fifth Avenue, Suite 3A, Pittsburgh, PA, 15213, USA. aabutt@pitt.edu.|University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. aabutt@pitt.edu.|Hamad Healthcare Quality Institute, Doha, Qatar. aabutt@pitt.edu.|Hamad Medical Corporation, Doha, Qatar. aabutt@pitt.edu.
authors.forename: Adeel A
authors.initials: AA
authors.lastname: Butt
authors.affiliation: VA Pittsburgh Healthcare System, 3601 Fifth Avenue, Suite 3A, Pittsburgh, PA, 15213, USA. peng.yan@va.gov.
authors.forename: Peng
authors.initials: P
authors.lastname: Yan
authors.affiliation: Massachusetts General Hospital, Boston, MA, USA. tgsimon@partners.ord.
authors.forename: Tracey G
authors.initials: TG
authors.lastname: Simon
authors.affiliation: Massachusetts General Hospital, Boston, MA, USA. rtchung@partners.org.
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Chung
authors.affiliation: Hamad Medical Corporation, Doha, Qatar. asamra@hamad.qa.
authors.forename: Abdul-Badi
authors.initials: AB
authors.lastname: Abou-Samra
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D005260:Female; D006526:Hepatitis C / Q000097:blood*; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008103:Liver Cirrhosis / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008055:Lipids; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol